

Amendments to the Claims

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A transgenic mouse whose genome comprises a transgene comprising a mouse FGF1B promoter or human FGF1B promoter, operably linked to a DNA fragment comprising a sequence encoding the SV40 large T antigen, that wherein said mouse comprises brain tumor cells that do not express glial fibrillary acidic protein, S-100, synaptophysin and neuron-specific enolase ~~and a genome that comprises a transgene comprising: a mouse FGF1B promoter or human FGF1B promoter.~~

2-4 canceled

5. (currently amended) The transgenic mouse of claim 1, wherein the promoter comprises nucleotide -540 through nucleotide +31 of the human FGF1B promoter, ~~and wherein nucleotides -540 to +31 of the human FGF1B promoter are the same depicted in SEQ ID NO: 2~~ as nucleotide 10 to nucleotide 580 of ~~SEQ ID NO: 2~~.

6. (previously presented) The transgenic mouse of claim 1, wherein the promoter comprises nucleotide 10 to nucleotide 580 of SEQ ID NO: 2, and wherein the DNA fragment comprises nucleotides 5171-2533 of the SV40 immediate early gene.

7-14 (canceled)

15. (previously presented) A method for identifying a drug which is effective at inhibiting growth of brain tumors in the transgenic mouse of claim 1, wherein said brain tumors comprise cells that do not express glial fibrillary acidic protein, S-100, synaptophysin and neuron-specific enolase, the method comprising:

- a) administering a candidate drug to the transgenic mouse of claim 1; and
- b) assaying for the growth of said brain tumors in said transgenic mouse, wherein an inhibition of growth of said brain tumors in said mouse as compared to transgenic mice of claim

1 which have not received the candidate drug indicates that said candidate drug is effective at inhibiting the growth of said brain tumors in said transgenic mouse.

16. (currently amended) A brain tumor cell line derived from the tumor cells of the transgenic mouse of claim 1, wherein said tumor cell line does not express glial fibrillary acidic protein, S-100, synaptophysin and neuron-specific enolase.

17. (previously presented) The tumor cell line of claim 16, wherein the genome of said transgenic mouse comprises a transgene comprising nucleotide 10 to nucleotide 580 of SEQ ID NO: 2.

18. (previously presented) The tumor cell line of claim 16, wherein the genome of said transgenic mouse comprises a transgene comprising nucleotide 43 to nucleotide 580 of SEQ ID NO: 2.

19. (currently amended) The tumor cell line of claim 16, wherein the cell line has ATCC Patent Deposit Designation No. PTA-3661.

20-39 canceled

40. (previously presented) The transgenic mouse of claim 1, wherein the sequence of the promoter is set forth in SEQ ID NO. 3.

41. (previously presented) The transgenic mouse of claim 1, wherein the promoter comprises nucleotide 43 to nucleotide 580 of SEQ ID NO: 2, and wherein the DNA fragment comprises nucleotides 5171-2533 of the SV40 immediate early gene.

42. (previously presented) The method of claim 15, wherein the candidate drug is administered to the transgenic mouse intracerebrally or by intravenous injection.